Transcriptional landscape of psoriasis identifies the involvement of IL36 and IL36RN

BMC Genomics

Külli Kingo¹  Kristi Abram¹  Ele Prans²  Ene Reimann²  Sulev Kõks²  Maris Keermann¹ 

[1]Department of Dermatology, Tartu University Hospital, Tartu, Estonia

[2]Department of Reproductive Biology, Estonian University of Life Sciences, Tartu, Estonia

关键词: Functional genomics;    High-throughput nucleotide sequencing;    Gene expression profiling;    Transcriptome;    Psoriasis;   

Others  :  1177270
DOI  :  10.1186/s12864-015-1508-2

 received in 2014-09-28, accepted in 2015-03-30,  发布年份 2015

【 摘 要 】

Background

In present study we performed whole transcriptome analysis in plaque psoriasis patients and compared lesional skin with non-lesional skin and with the skin from healthy controls. We sequenced total RNA from 12 lesional (LP), 12 non-lesional (NLP) and from 12 normal (C) skin biopsies.

Results

Compared with previous gene expression profiling studies we had three groups under analysis - LP, NLP and C. Using NLP samples allows to see the transcriptome of visually normal skin from psoriasis patient. In LP skin S100A12, S100A7A, LCE3E, DEFB4A, IL19 were found up regulated. In addition to already these well-described genes, we also found several other genes related to psoriasis. Namely, KLK9, OAS2, OAS3, PLA2G, IL36G, IL36RN were found to be significantly and consistently related to the psoriatic lesions and this finding is supported also by previous studies. The genes up-regulated in the LP samples were related to the innate immunity, IL17 and IL10 networks. In NLP samples innate immunity and IL17 network were activated, but activation of IL10 network was not evident. The transcriptional changes characteristic in the NLP samples can be considered as a molecular signature of “dormant psoriasis”.

Conclusions

Taken together, our study described the transcriptome profile characteristic for LP and NLP psoriatic skin. RNA profile of the NLP skin is in between the lesional and healthy skin, with its own specific pattern. We found that both LP and NLP have up-regulated IL17 network, whereas LP skin has up regulated IL10 related cytokines (IL19, IL20, IL24). Moreover, IL36G and IL36RN were identified as strong regulators of skin pathology in both LP and NLP skin samples, with stronger influence in LP samples.

【 授权许可】

   
2015 Keermann et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Nestle FO, Kaplan DH, Barker J: Psoriasis. N Engl J Med 2009, 361(5):496-509.
• [2]Lebwohl M: Psoriasis. Lancet 2003, 361(9364):1197-204.
• [3]Lowes MA, Suarez-Farinas M, Krueger JG: Immunology of psoriasis. Annu Rev Immunol 2014, 32:227-55.
• [4]Liu Y, Helms C, Liao W, Zaba LC, Duan S, Gardner J, et al.: A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 2008, 4(3):e1000041.
• [5]Kõks S, Kingo K, Rätsep R, Karelson M, Silm H, Vasar E: Combined haplotype analysis of the interleukin-19 and −20 genes: relationship to plaque-type psoriasis. Genes Immun 2004, 5(8):662-7.
• [6]Kõks S, Kingo K, Vabrit K, Rätsep R, Karelson M, Silm H, et al.: Possible relations between the polymorphisms of the cytokines IL-19, IL-20 and IL-24 and plaque-type psoriasis. Genes Immun 2005, 6(5):407-15.
• [7]Bowcock AM, Shannon W, Du F, Duncan J, Cao K, Aftergut K, et al.: Insights into psoriasis and other inflammatory diseases from large-scale gene expression studies. Hum Mol Genet 2001, 10(17):1793-805.
• [8]Gudjonsson JE, Ding J, Johnston A, Tejasvi T, Guzman AM, Nair RP, et al.: Assessment of the psoriatic transcriptome in a large sample: additional regulated genes and comparisons with in vitro models. J Invest Dermatol 2010, 130(7):1829-40.
• [9]Swindell WR, Johnston A, Voorhees JJ, Elder JT, Gudjonsson JE: Dissecting the psoriasis transcriptome: inflammatory- and cytokine-driven gene expression in lesions from 163 patients. BMC Genomics 2013, 14:527. BioMed Central Full Text
• [10]Gudjonsson JE, Ding J, Li X, Nair RP, Tejasvi T, Qin ZS, et al.: Global gene expression analysis reveals evidence for decreased lipid biosynthesis and increased innate immunity in uninvolved psoriatic skin. J Invest Dermatol 2009, 129(12):2795-804.
• [11]Suarez-Farinas M, Lowes MA, Zaba LC, Krueger JG: Evaluation of the psoriasis transcriptome across different studies by gene set enrichment analysis (GSEA). PLoS One 2010, 5(4):e10247.
• [12]Li B, Tsoi LC, Swindell WR, Gudjonsson JE, Tejasvi T, Johnston A, et al.: Transcriptome Analysis of Psoriasis in a Large Case–control Sample: RNA-Seq Provides Insights into Disease Mechanisms. J Invest Dermatol 2014, 134(7):1828-38.
• [13]Jabbari A, Suarez-Farinas M, Dewell S, Krueger JG: Transcriptional profiling of psoriasis using RNA-seq reveals previously unidentified differentially expressed genes. J Invest Dermatol 2012, 132(1):246-9.
• [14]McCarthy DJ, Chen Y, Smyth GK: Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. Nucleic Acids Res 2012, 40(10):4288-97.
• [15]Robinson MD, McCarthy DJ, Smyth GK: edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010, 26(1):139-40.
• [16]Storey JD, Tibshirani R: Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 2003, 100(16):9440-5.
• [17]Lo YH, Torii K, Saito C, Furuhashi T, Maeda A, Morita A: Serum IL-22 correlates with psoriatic severity and serum IL-6 correlates with susceptibility to phototherapy. J Dermatol Sci 2010, 58(3):225-7.
• [18]Bonifati C, Solmone M, Trento E, Pietravalle M, Fazio M, Ameglio F: Serum interleukin-6 levels as an early marker of therapeutic response to UVB radiation and topical steroids in psoriatic patients. Int J Clin Lab Res 1994, 24(2):122-3.
• [19]Johnston A, Xing X, Guzman AM, Riblett M, Loyd CM, Ward NL, et al.: IL-1F5, −F6, −F8, and -F9: a novel IL-1 family signaling system that is active in psoriasis and promotes keratinocyte antimicrobial peptide expression. J Immunol 2011, 186(4):2613-22.
• [20]Russell CB, Rand H, Bigler J, Kerkof K, Timour M, Bautista E, et al.: Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody. J Immunol 2014, 192(8):3828-36.
• [21]Ainali C, Valeyev N, Perera G, Williams A, Gudjonsson JE, Ouzounis CA, et al.: Transcriptome classification reveals molecular subtypes in psoriasis. BMC Genomics 2012, 13:472. BioMed Central Full Text
• [22]Zhou X, Krueger JG, Kao MC, Lee E, Du F, Menter A, et al.: Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics 2003, 13(1):69-78.
• [23]Reischl J, Schwenke S, Beekman JM, Mrowietz U, Sturzebecher S, Heubach JF: Increased expression of Wnt5a in psoriatic plaques. J Invest Dermatol 2007, 127(1):163-9.
• [24]Yao Y, Richman L, Morehouse C, de los Reyes M, Higgs BW, Boutrin A, et al.: Type I interferon: potential therapeutic target for psoriasis? PLoS One 2008., 3(7) Article ID e2737
• [25]Zaba LC, Suarez-Farinas M, Fuentes-Duculan J, Nograles KE, Guttman-Yassky E, Cardinale I, et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol. 2009;124(5):1022–1010 e1021-1395.
• [26]Suarez-Farinas M, Li K, Fuentes-Duculan J, Hayden K, Brodmerkel C, Krueger JG: Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J Invest Dermatol 2012, 132(11):2552-64.
• [27]Tian S, Krueger JG, Li K, Jabbari A, Brodmerkel C, Lowes MA, et al.: Meta-analysis derived (MAD) transcriptome of psoriasis defines the "core" pathogenesis of disease. PLoS One 2012, 7(9):e44274.
• [28]Joyce CE, Zhou X, Xia J, Ryan C, Thrash B, Menter A, et al.: Deep sequencing of small RNAs from human skin reveals major alterations in the psoriasis miRNAome. Hum Mol Genet 2011, 20(20):4025-40.
• [29]Swindell WR, Xing X, Voorhees JJ, Elder JT, Johnston A, Gudjonsson JE: Integrative RNA-seq and microarray data analysis reveals GC content and gene length biases in the psoriasis transcriptome. Physiol Genomics 2014, 46(15):533-46.
• [30]Kulka M, Calvo MS, Ngo DT, Wales SQ, Goswami BB: Activation of the 2-5OAS/RNase L pathway in CVB1 or HAV/18f infected FRhK-4 cells does not require induction of OAS1 or OAS2 expression. Virology 2009, 388(1):169-84.
• [31]Grammatikos AP, Kyttaris VC, Kis-Toth K, Fitzgerald LM, Devlin A, Finnell MD, et al.: A T cell gene expression panel for the diagnosis and monitoring of disease activity in patients with systemic lupus erythematosus. Clin Immunol 2014, 150(2):192-200.
• [32]Wolk K, Witte K, Witte E, Raftery M, Kokolakis G, Philipp S, et al.: IL-29 is produced by T(H)17 cells and mediates the cutaneous antiviral competence in psoriasis. Sci Transl Med 2013, 5(204):204ra129.
• [33]Swindell WR, Johnston A, Xing X, Voorhees JJ, Elder JT, Gudjonsson JE: Modulation of epidermal transcription circuits in psoriasis: new links between inflammation and hyperproliferation. PLoS One 2013, 8(11):e79253.
• [34]Sun GY, Chuang DY, Zong Y, Jiang J, Lee JC, Gu Z, et al.: Role of Cytosolic Phospholipase A in Oxidative and Inflammatory Signaling Pathways in Different Cell Types in the Central Nervous System. Molecular neurobiology 2014, 50(1):6-14.
• [35]Kumar S, McDonnell PC, Lehr R, Tierney L, Tzimas MN, Griswold DE, et al.: Identification and initial characterization of four novel members of the interleukin-1 family. J Biol Chem 2000, 275(14):10308-14.
• [36]Bachmann M, Scheiermann P, Hardle L, Pfeilschifter J, Muhl H: IL-36gamma/IL-1F9, an innate T-bet target in myeloid cells. J Biol Chem 2012, 287(50):41684-96.
• [37]Dinarello CA: Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011, 117(14):3720-32.
• [38]Vigne S, Palmer G, Lamacchia C, Martin P, Talabot-Ayer D, Rodriguez E, et al.: IL-36R ligands are potent regulators of dendritic and T cells. Blood 2011, 118(22):5813-23.
• [39]DaErme AM, Wilsmann-Theis D, Wagenpfeil J, Holzel M, Ferring-Schmitt S, Sternberg S, et al.: IL-36gamma (IL-1F9) is a Biomarker for Psoriasis Skin Lesions. J Invest Dermatol 2014, 135(4):1025-32.
• [40]Swindell WR, Stuart PE, Sarkar MK, Voorhees JJ, Elder JT, Johnston A, et al.: Cellular dissection of psoriasis for transcriptome analyses and the post-GWAS era. BMC Med Genet 2014, 7:27.
• [41]Garlanda C, Dinarello CA, Mantovani A: The interleukin-1 family: back to the future. Immunity 2013, 39(6):1003-18.
• [42]Martin DA, Towne JE, Kricorian G, Klekotka P, Gudjonsson JE, Krueger JG, et al.: The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol 2013, 133(1):17-26.